Skip to main content
. 2015 Jul 1;8(7):7798–7808.

Table 1.

The results of consensus and interobserver evaluation

CONSENSUS INTEROBSERVER
Case MRI
Histopathology** Cytology IHC Tissue Cytology Diagnosis


G SL SLM PVL PVLM PVLB LB NE V P1 P2 P3 P1 P2 P3 P1 P2 P3
1 Enhancing lesion with a mass effect in the left thalamus 1 target 7 targets 1 target 1 target + Ac CD20: +++ B B B Ac Ac NDc D D D
CD3: +
CD3: +
3 Multiple enhancing lesions in deep gray structures 2 targets 4 targets 2 targets 1 target Lc CD20: +++ B B B Ac Ac NDc D D D
CD3: +
4 Enhancing lesion with mass effect in left parietal lobe 1 target 2 targets 3 targets 3 targets Bc CD20: +++ B B B Bc Bc Bc D D D
CD3: +
CD3: +
6 Multiple enhancing lesions in corpus callosum, right and left parietal lobe 4 targets 4 targets 2 targets + Bc CD20: +++ B B B Bc Bc Bc D D D
CD3: +
7 Periventricular enhancement 9 targets Bc CD20: +++ B B B Bc Bc Bc D D D
CD3: +
8 Enhancing lesion with mass effect in frontotemporal region 2 targets 8 targets Bc CD20: +++ B B B Bc Bc Bc D D D
CD3: +
9 Enhancing lesion with mass effect in right frontal lobe 2 targets 7 targets Bc CD20: +++ B B B Bc Bc Bc D D D
CD3: +
10 Multiple enhancing lesions in right temporal lobe and thalamus 1 target 3 targets 4 targets Bc CD20: +++ B B B Bc Bc Bc D D D
CD3: +
11 Enhancing lesion with mass effect in right parietal lobe 1 target 5 targets Bc CD20: +++ B B B Bc Bc Bc D D D
CD3: +
12 Enhancing lesion with mass effect in right parietal lobe 1 target 2 targets 4 targets Bc CD20: +++ B B B Bc Bc Bc D D D
CD3: +
13 Periventricular enhancement 1 target 1 target 6 targets Ac CD20: +++ A A N Ac Ac NDc D D S
CD3:+
14 Enhancing lesions in left cerebral hemisphere 4 targets 6 targets Lc CD20:+++ N N N NDc Ac NDc ND ND ND
CD3: +
15 Enhancing lesion in left thalamus, internal capsule, corpus callosum 2 targets 5 targets 3 targets Lc CD20: +++ B A A Ac Ac NDc D D S
CD3: +
16 Left parietal mass with rim enhancement 5 targets 2 targets 1 target 1 targets Lc CD20: ++ N N N NDc Ac NDc ND ND ND
CD3: ++
17 Patchy T2 signal in both hemispheres 4 targets 4 targets 2 targets Lc * A N N NDc NDc NDc S S ND
CD20: +++
CD3: +
18 Enhancing lesion in left-right temporal lobe, corpus callosum 3 targets 2 targets 1 target 1 target Lc CD20: ++ N N N NDc NDc NDc ND ND ND
CD3: ++
19 Multiple enhancing lesions in left thalamus and corpus callosum 2 targets 3 targets 1 target 1 target + Lc CD20: + A N N NDc NDc NDc ND ND ND
CD3: +++
20 Enhancing lesion in left and right thalamus, internal capsule, corpus cal3losum 3 targets 5 targets 1 target NLc CD20: ++ N N N NDc NDc NDc ND ND ND
CD3: ++
21 Enhancing lesion with mass effect in right frontotemporal region 5 targets 5 targets NLc CD20: ++ N N N NDc NDc NDc ND ND ND
CD3: ++
22 Multilocular enhancing lesion with mass effect in right temporal and occipital lobes 8 targets NLc CD20: ++ N N N NDc NDc NDc ND ND ND
CD3: ++
23 Enhancing lesion with mass effect in left parietooccipital region 2 targets 3 targets 3 targets Lc * A A N NDc NDc NDc D S ND
CD20: +++
CD3: +
24 Enhancement in left deep structures and contralaterally some small enhancing lesions 8 targets NLc N N N NDc NDc NDc ND ND ND
25 Left deep temporal mass with rim enhancement 7 targets NLc N N N NDc NDc NDc ND ND ND
*

Co-dominance in SL targets;

**

Artefacted targets are not included in the table.

G: Non-neoplastic glial tissue. SL:Sparse lymphoid cells. SLM: Sparse macrophages and lymphocytes. PVL: Perivascular normal appearing lymphocytes. PVLM: Perivascular lymphoid cells and macrophages. PVLB: Perivascular lymphocytes intermingled with blasts. LB: Diffuse neoplastic infiltration with blasts. NE: Necrosis V: Infiltration/fragmentation of vessel wall. Ac: Suspicious lymphoid atypia. Lc: Normal lymphocytes with or without macrophages. Bc: Lymphoid cells with blasts. NLc: A few or no lymphoid cells. B: Blasts A: Suspicious atypia. N: Normal appearing lymphocytes. NDc: Non-diagnostic cytology. D: Diagnostic. S: Suspicious. ND: Non-diagnostic. P1: Pathologist 1. P2:Pathologist 2. P3: Pathologist 3.